Last reviewed · How we verify
COVID-19 vaccination
COVID-19 vaccines train the immune system to recognize and neutralize the SARS-CoV-2 virus by inducing antibody and T-cell responses against viral antigens.
COVID-19 vaccines train the immune system to recognize and neutralize the SARS-CoV-2 virus by inducing antibody and T-cell responses against viral antigens. Used for Prevention of COVID-19 infection and severe disease caused by SARS-CoV-2.
At a glance
| Generic name | COVID-19 vaccination |
|---|---|
| Also known as | the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccination, Moderna mRNA-1273 vaccine, Moderna (mRNA-1273), Pfizer (BTN162b2), Janssen (Ad26.COV2.S) |
| Sponsor | University Medical Center Groningen |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
COVID-19 vaccines work by introducing viral antigen (either mRNA encoding spike protein, inactivated virus, or viral vector) to stimulate both humoral and cellular immune responses. This priming enables rapid recognition and clearance of SARS-CoV-2 upon exposure, reducing severity of infection and transmission. Multiple vaccine platforms have been deployed globally, including mRNA (Pfizer-BioNTech, Moderna), viral vector (AstraZeneca, Johnson & Johnson), and inactivated virus vaccines.
Approved indications
- Prevention of COVID-19 infection and severe disease caused by SARS-CoV-2
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
- Nausea
Key clinical trials
- Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) (NA)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks (NA)
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-19 vaccination CI brief — competitive landscape report
- COVID-19 vaccination updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI